National Quality Infrastructure and Local Pharmaceutical Manufacturing in Ethiopia: A Qualitative Analysis of System Gaps and Strategic Reforms

Every time a factory makes medicine, it relies on invisible tools to ensure the final product is safe and effective. These tools are not just the machines mixing the drugs, but the rulers, scales, and sensors that measure temperature, pressure, and chemical purity. If a scale is off by a fraction of a gram, or a thermometer reads the wrong temperature, the medicine could fail to work or even harm a patient. To keep these measuring tools accurate, they must be checked against trusted standards, a process called calibration. This entire network of standards, testing, and verification is known as a National Quality Infrastructure. It acts as the backbone for any country trying to make its own medicines, ensuring that local factories can produce drugs that meet global safety rules. Without this system, a country remains dependent on importing medicine from abroad, leaving its population vulnerable when supply chains break.

In Ethiopia, a nation with a growing population and a strategic goal to produce its own medicines, researchers recently investigated how well this quality system is working for local drug makers. The study, conducted by Addisu Afrassa Tegegne from the University of Gondar, did not look at the medicines themselves, but at the support system behind them. The researcher wanted to understand if the country's institutions for measuring, testing, and certifying quality were strong enough to help local factories compete. To find out, the researcher spoke with twenty-two key people, including managers at pharmaceutical factories, officials from the national drug regulator, and experts from the institutions responsible for quality standards. These conversations took place in offices across the country, lasting about an hour each, and were recorded and analyzed to find common patterns in what the experts were saying.

The investigation revealed a system that is struggling to keep up with the needs of the industry. While the factories are eager to make more medicine, they find that the local support system is incomplete. Most of the factory managers said they only interact with one part of the quality system: the national metrology institute, which handles basic calibration for simple tools like weighing scales. However, the more complex and critical measurements, such as checking the sensors that monitor humidity and temperature in the air-handling systems, cannot be done locally. As a result, about eighty percent of these essential calibration services are sent to foreign providers in countries like India, China, and Egypt. This dependence is costly and slow, creating a bottleneck for local production. The researchers found that the local institutions simply do not have the equipment or the trained staff to handle these advanced tests.

Another major gap is the lack of independent testing laboratories. In a healthy system, a factory should be able to send a sample of its raw materials or finished drug to a third-party lab for verification. In Ethiopia, however, there is no dedicated, accredited laboratory for testing pharmaceuticals. The national drug regulator is currently the only body capable of performing these tests, which creates a conflict of interest and a heavy workload. The regulator is meant to oversee the industry, not act as its primary testing service. Because of this, factories often have to wait for results or send samples abroad, delaying their ability to bring new medicines to market. Furthermore, while some factories have obtained international certificates for their management systems, very few have achieved the specific laboratory accreditation needed to prove their testing equipment is world-class.

The study also highlighted a disconnect in how the different parts of the system talk to each other. The institutions responsible for setting standards, checking measurements, and accrediting labs operate in isolation from the drug regulator and the factories. There is no single national policy that ties these groups together, leading to confusion and missed opportunities. Factory managers often do not understand the full range of services available to them, thinking that quality infrastructure is just about getting a certificate for a tender rather than a tool for improving their actual production. Meanwhile, the institutions face their own struggles, including a shortage of skilled workers who often leave for better-paying jobs in the private sector, and a lack of funding to buy the expensive equipment needed to expand their services.

To fix these problems, the researchers proposed a set of practical steps that focus on building a more connected and capable system. They suggested that the government should encourage private companies to open their own calibration and testing labs, which would relieve the pressure on public institutions and give factories more choices. The study also emphasized the need for better training, not just for the factory workers, but for the university students who will become the next generation of engineers and scientists. By updating university curriculums to include quality systems and metrology, the country can ensure a steady supply of skilled professionals. Finally, the researchers argued that the drug regulator and the quality institutions must work together more closely, creating a unified strategy that makes it clear why meeting high standards is essential for the future of Ethiopian medicine.

The findings paint a clear picture: Ethiopia has the ambition to manufacture its own life-saving drugs, but the foundation required to do so safely and efficiently is still under construction. The country has the factories and the desire, but it lacks the full network of local experts, tools, and coordinated policies needed to verify that every pill is perfect. Without strengthening this invisible infrastructure, the goal of self-sufficiency in medicine will remain out of reach, and the country will continue to rely on others to ensure the safety of its people's health. The path forward requires not just building more factories, but building the trust and technical capacity that makes those factories reliable.